cyrilzakka/clinical-trials huggingface dataset:
EXOME Analysis Position in the Strategy of Genetic Predisposition Factors Identification in Early-onset Cancer

5 to 10% of cancers are due to the presence of a constitutional genetic alteration. It can be inherited from parents (family form) or by accident, in the first moments of life after fertilization (sporadic form). In both cases, this genetic alteration is constitutional and transmissible to descendants. It is hereditary. When an hereditary early form is suspected, several well-known genes generally involved in genetic predispositions to cancer are found by a technique called " gene panel ". However, this analysis does not always identify the genetic predisposing factors for cancer. New techniques called "high-throughput exome sequencing (SHD-E)", allow more than the analysis of the the gene panel. These analysis allow to identify alterations in other genes that could contribute to the development of cancer. The objective of the Ex²trican study is to show, from patients with early cancer (sporadic or familial form), that this approach to exome sequencing can be effective to identify new genetic risk of cancer, when the first panel analysis of genes is negative.

The main objective of this study is to evaluate the interest of the SHD-E approaches after a negative result of the analysis called " gene panel " tested in routine in order to identify a genetic factor of predisposition to the cancer.

Eligibility Criteria:
Inclusion Criteria:

Index case:

1. Major or minor patient
2. Histological or cytological evidence of malignant tumor diagnosis
3. Patient with cancer before age 40 (or before age 30 for breast cancer).
4. Absence of anomaly found on the oncogenetic panel tested in the predisposition concerned
5. Patient affiliated to a social security scheme
6. Signature of Informed Consent EXTRICAN
7. Availability of a tumor sample if needed secondary functional studies
8. Availability of both parents when the trio approach will be necessary in the population 1 (or validation of the indication in CPR in case of non-availability of both parents)
9. Availability of affected relatives in population 2 (or validation of the indication in SPC in case of non-availability of the related person)

Related:

1. Major or minor patient
2. Histological or cytological evidence of the diagnosis of malignant tumor if
3. Patient affiliated to a social security scheme
4. Signing informed consent EXTRICAN

Exclusion Criteria:

Index and related case:

1. Refusal of the patient participation
2. Psychiatric illness and / or condition of the patient compromising the understanding of the information or the realization of the study
3. Patient under guardianship, curatorship or safeguard of justice
4. Pregnant woman
Apixaban, Warfarin and Aspirin Prevents Portal Vein Thrombosis in Patients After Laparoscopic Splenectomy（ESAWAAPT）

The purpose of this study is to determine whether Apixaban, Warfarin and Aspirin Anticoagulation are effective and safe in Prevention of Portal Vein Thrombosis in Liver Cirrhotic Patients after Laparoscopic Splenectomy

After successful screening the cases of cirrhosis of liver irrespective of the etiology who have no portal vein thrombosis will be enrolled. The baseline Doppler parameter will be recorded and the patient will be randomized into apixaban, warfarin or aspirin group. From postoperative day three, patients in apixaban group will receive oral Apixaban 2.5mg bid for six months, patients in warfarin group will receive oral Warfarin 2.5mg qd with titration of dose to maintain a target INR of 2-3 for six months, patients in aspirin group will receive oral Aspirin Enterie Ccoated Tablets 100mg qd for six months. All groups will be along with five days of subcutaneous injection of Low Molecular Weight Heparin and three months of oral Dipyridamole. Every three months the Doppler screening for the occurrence of portal vein thrombus (PVT) or spleno-mesenteric thrombosis will be done for all patients. All groups will receive the therapy for six months irrespective of the Doppler findings in relation to portal vein thrombus occurrence. Then six months monitoring will be done in the three groups as per the primary or secondary outcome.

Eligibility Criteria:
Inclusion Criteria:

* A clinical, radiological or histologic diagnosis of cirrhosis of any etiology
* Splenomegaly with secondary hypersplenism
* No evidence of PVT or spleno-mesenteric thrombosis by ultrasound evaluation and angio-CT
* Informed consent to participate in the study

Exclusion Criteria:

* Hepatocellular carcinoma or any other malignancy
* Hypercoagulable state other than the liver disease related
* DRUGS- oral contraceptives, anticoagulation or anti-platelet drugs
* Base line INR \>2
* Child-Pugh grade C
* Recent peptic ulcer disease
* History of Hemorrhagic stroke
* Pregnancy
* Uncontrolled Hypertension
* Human immunodeficiency virus (HIV) infection
Pleth Variability Index and Hypotension

Correct assessment of a patient's volume status is the most important goal for an anesthetist. However, most of the variables used for fluid response evaluation are invasive and technically challenging.Pulse oximeter is a non-invasive, standardized and widely used monitoring method in many countries. Our aim in this study is to investigate the usefulness of the noninvasive pleth variability index to predict hypotension in orthopedic hip fracture patients who underwent spinal anesthesia.


Eligibility Criteria:
Inclusion Criteria:

* over 65 years old
* Patients to undergo spinal anesthesia

Exclusion Criteria:

* Patients under 65 years old
* Patients to undergo general anesthesia or only sedation
* Patients with cardiac arrhythmia
* Patients with low ventricular ejection fraction
* Heart valve disease patients
The Effect of Emotional Freedom Technique on Mental Well-Being and Stress Level in Pregnant Women

Emotional freedom technique will be applied to women with risky pregnancy. Emotional freedom technique group and control groups each consisted of 60 pregnant women.

Objective In this experimental study, it was aimed to examine the effect of emotional freedom technique applied to women with risky pregnancy on mental well-being and stress levels.

Materials and Methods: This randomized controlled study will be conducted between February 2024 and August 2024 in Kahramanmaraş Necip Fazıl City Hospital Obstetrics and Gynecology Annex Building Obstetrics Outpatient Clinics with a total of 120 risk pregnant women (60 EFT, 60 control). EFT will be applied in the study. Women in the EFT group will receive EFT four times at one-week intervals. Pretest data will be obtained by filling out the Personal Information Form, Warwick-Edinburgh Mental Well-Being Scale (WEMWB), Prenatal Distress Scale - Revised Version before the Emotional Freedom Technique application. After the interventions, post-test data will be obtained by completing the Warwick-Edinburgh Mental Well-Being Scale (WEMWB), Prenatal Distress Scale - Revised Version. In addition, the Subjective Units of Experience (SUE) scale will be administered before and after each EFT intervention.

Eligibility Criteria:
Inclusion Criteria:

* 18 years of age or older,
* Graduated from at least primary school
* Volunteering to participate in the research,
* Primiparous,
* Pregnant women who do not have conditions such as infection, wound, scar in the tapping areas.
* Pregnant women who meet any of the criteria in the Ministry of Health Risk Assessment Form for Pregnancy.

Exclusion Criteria:

* Pregnant women who participated in EFT or other antenatal classes/programs during the study period.
* Those who did not want to continue participating in the study,
* Those with a psychological problem according to the pregnant women's statements.
Effect of Self Assembling Peptide on White Spot Lesion

During re-mineralization of white spot lesion, Will biomimetic self-assembling peptides improve the re-mineralizating effect of the post orthodontic white spot lesion compared to fluoride-based delivery systems?

Conservative dentistry no longer prefers the "drill and fill" concept and advocates reversal of lesions via remineralization. . Remineralization is the process of restoring minerals - again, in the form of mineral ions - to the hydroxyapatite latticework structure. It is three-dimensional, and the lost ions must be replaced with ions having the exact same shape, size and the same electrical charge as those lost from the lattice.

Fluoride and self-assembling peptides have been used as adjuncts to enhance remineralization.

Eligibility Criteria:
Inclusion Criteria:

* Patients with post orthodontic white spot lesion.
* Patients with good oral hygiene.
* Patients with good general health.
* Cooperative patients.
* Subjects who signed the informed consent.

Exclusion Criteria:

* Patients with tetracycline pigmentation and dental fluorosis.
* Enamel cavitation.
* Disable patient.
* patient with any systemic disease or severe medical complications.
Impact of Transcutaneous Auricular Vagus Nerve Stimulation on Digestive Symptoms in Systemic Sclerosis Systemic Sclerosis

The purpose of this study is to assess the effect of transcutaneous auricular vagus nerve stimulation (ta-VNS) on gastrointestinal symptoms and quality of life in systemic sclerosis (SSc) patients.

Conduct of study:

Entry into the study: After informed consent, patients will be randomised into two arms (active or sham stimulation). The person responsible for setting the stimulator will make the randomization via an interactive web response system (IWRS). Only this person will have the knowledge of the group allocated to the patient.

Start of ta-VNS sessions according to the 1st modality of stimulation : The patient will perform 2 stimulation sessions per day at home for 3 months. During this period a clinical research associate will contact the patient to verify that he does not encounter any problems with the stimulator. An evaluation visit will be carried out at the end of these three months by a blind physician.

Wash-out period during 1 month.

Start of ta-VNS sessions according to the 2nd modality of stimulation : The patient will perform 2 stimulation sessions per day at home for 3 months. An evaluation visit will be conducted prior to the start of the sessions and another at the end of the sessions.

Eligibility Criteria:
Inclusion Criteria:

* SSc meeting ACR-EULAR (American College of Rheumatology- European League Against Rheumatism) criteria.
* Treatment by proton pump inhibitor (PPI) initiated for at least 3 months.
* Patient's written consent
* Affiliated with social security system

Exclusion Criteria:

* Patients who have previously received central or peripheral neurostimulation treatment regardless of indication.
* People equipped with an active pacemaker in the area of application of the stimulation electrodes.
* People with dermatological disease in the area of application of stimulation electrodes
* People with recent venous or arterial thrombosis (less than one month)
* People with a cochlear implant near the stimulation site
* People followed for proven heart disease
* Person who are protected under the act
* Pregnant or breastfeeding woman
The Application Effect of Modified Pressure-Reducing Fixation Protective Nasal Strip in the Nursing Care of Patients Receiving High-Flow Nasal Cannula Therapy

This study was a prospective, randomized controlled trial that included 60 patients receiving high-flow nasal cannula (HFNC) therapy. Participants were randomly divided into two groups: the observation group (n=30), which used a modified decompression fixation protective patch, and the control group (n=30), which received hydrocolloid dressing protection in addition to standard care. The study compared general demographic data, the interval time between changing fixation straps, the times of adjusting the catheter position, the effectiveness of skin management, the number of ineffective oxygenation attempts, the incidence of adverse events, and patient comfort scores between the two groups.


Eligibility Criteria:
Inclusion Criteria:

* 1. Meet the diagnostic criteria for respiratory failure, worsening dyspnea, acute exacerbation of chronic obstructive pulmonary disease (COPD), bronchitis, pneumonia, and congestive heart failure.
* 2. No severe cognitive impairment.
* 3. Good compliance and being able to actively cooperate with the investigation.
* 4. No concurrent metabolic diseases.

Exclusion Criteria:

* 1. Patients with severe respiratory failure, severe arrhythmias, concurrent pneumothorax, coma upon admission, or persistent vomiting.
* 2. Patients with severe liver failure, kidney failure, or other severe systemic diseases.
* 3. Patients with severe cognitive impairment who are unable to understand or comply with the study requirements.
* 4. Patients with severe hemodynamic instability.
* 5. Patients with allergies to oxygen therapy or protective patch materials.
Trial to Evaluate the Safety and Efficacy of Maraviroc in Patients Hospitalized for Coronavirus Disease 2019 (COVID-19)

Maraviroc (MVC) is a drug, very well tolerated, it has been seen that MVC has properties of modulating the immune system, exerting an anti-inflammatory effect in different diseases. In COVID-19, very high levels of inflammation occur that cause organs and systems to be damaged. MVC could reduce this inflammation achieving a better prognosis of COVID-19.

In this clinical trial the investigators want to evaluate if standard treatment together with Maraviroc (MVC) compared to standard treatment alone, achieves better clinical evolution in participants hospitalized for COVID-19.

Eligibility Criteria:
Inclusion Criteria:

* Subjects aged ≥ 18 years.
* Infection confirmed by SARS-CoV-2 by polymerase chain reaction (PCR) at least 3 days before randomization.
* Hospitalized or emergency patient in hospitalization phase.
* Mild / moderate pneumonia, with fever, persistent cough and severe asthenia, confirmed by imaging tests (conventional radiology or computerized axial tomography (CT)) with ambient air oxygen saturation (SatO2)\> 94%.
* Less than 12 days from the onset of symptoms.
* Women of childbearing potential must have a negative serum or urine pregnancy test prior to inclusion in the study and must commit to using highly effective contraceptive methods (intrauterine device, bilateral tubal occlusion, vasectomized partner, and sexual abstinence).
* Accepts written consent or oral informed in the case that due to the relevant security protocols, written consent is not possible.

Exclusion Criteria:

* Patient with severe pneumonia confirmed by imaging test (conventional radiology or computerized axial tomography (CT)) with ambient air oxygen saturation (SatO2) ≤94%.
* Another acute active infection other than that produced by SARS-CoV-2.
* Chronic renal failure (estimated glomerular filtration ≤ 30 ml / min / 1.73 m2 or receiving renal replacement therapy in any of its modalities).
* Known HIV infection. Unless the patient has\> 500 CD4 + / mm3 and an undetectable viral load for more than 6 months.
* Active co-infection with known hepatitis B or C viruses.
* Cirrhosis, portal hypertension and / or hypersplenism of any etiology.
* Past or current neoplasms subsidiary to treatment with steroids, immunomodulators or chemotherapy
* Laboratory abnormalities.
* Concomitant use of drugs with major pharmacological interactions with the study drugs, according to the respective technical specifications of the products.
* Pregnancy.
HIT in the Healthy Elderly Population

It is widely known that exercise improves general fitness and that fitter patients recover more easily from illness and surgery. Conversely, unfit patients have a significantly higher morbidity and mortality after surgery and a longer inpatient stay. This will become increasingly important in an aging population as baseline fitness generally declines with age.

One method of improving cardiovascular fitness is by using low intensity endurance training programmes, a disadvantage of these it that they can take several months to show improvement. High intensity interval training (HIT) programmes that use short episodes of high intensity exercise have also been shown to improve fitness. These HIT programmes have also shown improvement in functional capacity and quality of life in patients with chronic disease. An advantage of HIT is that improvements in fitness may occur in a shorter time than traditional endurance training. It is also known that HIT can give superior gains over endurance training.

The primary aim of this study is to determine whether an improvement in aerobic fitness, as judged by a 2ml/kg/min increase in VO2peak, can be achieved within 31 days via a HIT programme, in a group of healthy elderly volunteers.

As a secondary aim we will assess whether this programme would be acceptable to the group studied, through determination of subject compliance and adherence to the training programme.


Eligibility Criteria:
Inclusion Criteria:

* Good health
* Male and female
* 60 -75 years old

Exclusion Criteria:

* Uncontrolled hypertension (BP \> 140/100)
* Angina
* Heart failure (NYHA class III/IV)
* Cardiac arrthymias
* Right to left cardiac shunt
* Recent cardiac event
* Previous stroke/TIA
* Aneurysm (large vessel or intracranial)
* Severe respiratory disease including pulmonary hypertension
* COPD/asthma with an FEV1 less than 1.5 l
* Inclusion into any other research study in the last three months which involved: taking a drug; being paid a disturbance allowance; having an invasive procedure or exposure to ionising radiation
Brain Changes in Stimulant Dependent Subjects - 8

The purpose of this study is to identify the neurophysiologic indicators of cocaine or methamphetamine use and withdrawal, to examine the relationship between subjects' reports of depression, craving, and stimulant use, and neurophysiologic measures, and to identify neurophysiologic measures which can be used to identify new treatments for stimulant dependence.

By Incorporating QEEG into clinical trails, the plan is to develop physiologic markers of treatment efficacy, and to aid in the identification of effective treatments.

Eligibility Criteria:
Inclusion Criteria:

M/F ages 21-50. Meet DSM-IV criteria for cocaine dependence. Agree to conditions of the study and sign informed consent.

Exclusion Criteria:

Psychiatric disorder that requires medication therapy. History of seizures. Pregnant and/or nursing women. Dependence on ETOH or benzodiazepines or other sedative/hypnotics. Acute hepatitis. Other medical conditions that deem participation to be unsafe.
Frequencies of Histo-pathological Findings in Patients With Paraquat Toxicity

The purpose of this study is to determine frequencies of histo-pathological findings in dead poisoned patients and evaluate their relationships with age, gender, dosage of poisoning, time of admission and time of death.

Acute poisoning of paraquat which is taken either to commit suicide or by mistake has become a social problem in world. The present study was conducted to determine frequencies of histo-pathological findings in dead poisoned patients and evaluate their relationships with age, gender, dosage of poisoning, time of admission and time of death.

Eligibility Criteria:
Inclusion Criteria:

* every patients who dithionate test were positive

Exclusion Criteria:

* nothing
Open-label Berotralstat Access to HAE Patients Previously Enrolled in Berotralstat Studies

This is a phase 3b open-label study providing access to berotralstat for HAE patients who were previously enrolled in berotralstat studies.

APeX-A, 7353-312, is a single-arm, open-label, multicenter study. The study will be conducted in countries where berotralstat is not available either commercially or via another mechanism. All enrolled subjects will receive the planned marketed dose of berotralstat, 150 mg QD. The study will assess the long term safety and tolerability of berotralstat.

Eligible subjects will be enrolled directly into Study BCX7353-312 (Study 312) from Studies 302 and 204. Subjects will receive berotralstat 150 mg administered orally once daily (QD). Subjects will return to the clinic every 24 weeks for drug dispensation and safety monitoring for up to 240 weeks (approximately 5 years).

Safety and tolerability will be evaluated through assessment of serious adverse events (SAEs) and treatment-related, treatment-emergent adverse events (TEAEs). Up to 110 subjects are planned to enroll.

Eligibility Criteria:
Key Inclusion Criteria:

* Males and females currently enrolled in BioCryst-sponsored Study 302 or 204
* Able to provide written informed consent.
* Would benefit from continued berotralstat treatment
* Acceptable effective contraception

Key Exclusion Criteria:

* Pregnancy or breast-feeding
* Any condition or situation, including medical history that, in the opinion of the investigator or sponsor, would interfere with the subject's safety or ability to participate in the study
* Use of other medications for long-term prophylaxis of HAE attacks at the Baseline visit or any time during the study.
* Use of any other investigational medicinal product at the Baseline visit or any time during the study.
"Iris Shelf" Technique for Intraocular Foreign Bodies Removal

Intraocular foreign body (IOFB) injury is a common potentially serious form of ocular trauma. Metallic IOFB is the most common type of IOFB injury. Apart from the associated ocular tissue damage, Metallic IOFB may cause permanent visual impairment due to retinal toxicity and endophthalmitis.

When presenting posteriorly, the approach of IOFB removal is challenging. Several techniques had been described for posterior IOFB removal. All of these techniques aimed to remove IOFB with the least possible collateral damage. This study aims to describe "Iris shelf" technique for posterior IOFB removal through a clear corneal incision combined with phaco-vitrectomy and report its outcomes.


Eligibility Criteria:
Inclusion Criteria:

- posterior segment metallic IOFB who underwent combined phacovitrectomy with IOFB removal through a clear corneal incision using "Iris shelf" technique

Exclusion Criteria:

* Any other surgical technique for posterior segment IOFB removal
Research in Ethno-Medicine and Education (REMED)

The purpose of this study is to gain information about intravaginal practices, like intravaginal "twalet deba", among Haitian women living in South Florida. Intravaginal "twalet deba" may include douching, cleaning inside the vagina with different kinds of products, or using steam/vapor that enter the vagina. The investigators want to help learn the best way to increase early detection and/or prevention for cervical cancer. The investigators would like to know what plants, herbs, commercial products and medicines are used in these practices, how these products are prepared, applied, why these products are used, and how these products affect the vagina and cervix.


Eligibility Criteria:
Inclusion Criteria:

* 18 years of age or older
* Self-identifies as Haitian or Haitian-American
* Resident of Miami-Dade, Broward or Palm Beach County
* Currently engages in regular intravaginal cleansing practices that involve more than just water alone
* No history of hysterectomy
* Speaks Creole or English

Exclusion Criteria:

* Are adults unwilling or unable to provide consent
* Individuals less than 18 years of age
* Pregnant women
* Prisoners